Jaunuzņēmumi · 27.10.2026.1 min read
Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute
Vietējais automātiskais tulkojums · Avota oriģinālvaloda
Summary
OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Orphan Therapeutics Accelerator (OTXL) CAMBRIDGE, Mass., Oct. 27,…
Avota oriģinālvaloda: PR Newswire UK — News ReleasesAtvērt sākotnējo paziņojumu →